Cargando…
A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries
Background: Despite international initiatives on collaboration within the field of rare diseases, patient access to orphan medicinal products (OMPs) and healthcare services differ greatly between countries. This study aimed to create a comprehensive and in-depth overview of rare diseases policies an...
Autores principales: | Czech, Marcin, Baran-Kooiker, Aleksandra, Atikeler, Kagan, Demirtshyan, Maria, Gaitova, Kamilla, Holownia-Voloskova, Malwina, Turcu-Stiolica, Adina, Kooiker, Coen, Piniazhko, Oresta, Konstandyan, Natella, Zalis'ka, Olha, Sykut-Cegielska, Jolanta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997877/ https://www.ncbi.nlm.nih.gov/pubmed/32117845 http://dx.doi.org/10.3389/fpubh.2019.00416 |
Ejemplares similares
-
Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs—a Systematic Literature Review. Next Steps in Methodology Development?
por: Baran-Kooiker, Aleksandra, et al.
Publicado: (2018) -
Population norms of health-related quality of life in Moscow, Russia: the EQ-5D-5L-based survey
por: Hołownia-Voloskova, Malwina, et al.
Publicado: (2020) -
Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges
por: Daubner-Bendes, Rita, et al.
Publicado: (2021) -
Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries
por: Atikeler, Enver Kagan, et al.
Publicado: (2016) -
Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)